Predicine is a California-based molecular insights company that has developed a NGS liquid biopsy technology to measure cfDNA and cfRNA genomic alterations in blood or urine. Predicine has launched its 152-gene PredicineCARE and 600-gene PredicineATLAS liquid biopsy tests for detecting cancer variants (TMB, MSI, HRD, and gene deletion), monitoring efficacy/disease burden, and assessing minimal residual disease. Partnering with leading biopharmas, Predicine provides harmonized liquid biopsy tests and CDx development to support global clinical trials in US, EU, APAC region including China.